Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Issues Earnings Results

Posted by George Bondi on May 15th, 2026

Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($2.23) earnings per share (EPS) for the quarter, Zacks reports.

Here are the key takeaways from Valion Bio, Inc. Common Stock’s conference call:

Valion Bio highlighted a major regulatory milestone for Entolimod: NIAID provided the first FDA-precedent gastrointestinal study protocol and will fully fund the BLA-enabling in vivo program, shifting the Animal Rule pathway to a federally supported effort.
Management said Velocity Bioworks is now operational, with roughly 45 employees on site and a successful 200-fold manufacturing scale-up completed on time and within budget, positioning it as the company’s nearest-term revenue opportunity.
The company reiterated that Entolimod has broad government interest, including briefings with the U.S. Department of War and a request for information from Ukraine, which management says supports its potential use as a medical countermeasure for acute radiation syndrome.
Valion Bio outlined a longer-term push into oncology supportive care, with physician-sponsored neutropenia studies expected to begin in the second half of 2026 and six institutional sites already expressing interest.
First-quarter financials showed higher spending after the company’s biopharma pivot, with operating expenses rising to $5.6 million, net loss widening to $6.2 million, and cash falling to $7.2 million from $12.6 million at year-end, underscoring continued financing needs.

Valion Bio, Inc. Common Stock Stock Down 3.9%

Shares of VBIO opened at $0.93 on Friday. The company has a quick ratio of 20.13, a current ratio of 20.13 and a debt-to-equity ratio of 0.38. The stock has a market cap of $2.92 million, a price-to-earnings ratio of -0.14 and a beta of 1.86. The company has a 50-day moving average price of $1.01 and a two-hundred day moving average price of $1.37. Valion Bio, Inc. Common Stock has a 12 month low of $0.72 and a 12 month high of $5.60.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a report on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Valion Bio, Inc. Common Stock has an average rating of “Sell”.

Get Our Latest Report on Valion Bio, Inc. Common Stock

About Valion Bio, Inc. Common Stock

(Get Free Report)

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.